[{"address1": "4870 Sadler Road", "address2": "Suite 300", "city": "Glen Allen", "state": "VA", "zip": "23060", "country": "United States", "phone": "804 487 8196", "website": "https://www.adialpharma.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. The company's lead product is AD04, a serotonin-3 antagonist, which is in Phase 3 clinical trials for the treatment of alcohol use disorder. It is also involved in the development of drug candidates for non-opioid pain reduction and other diseases and disorders. The company was founded in 2010 and is based in Glen Allen, Virginia.", "fullTimeEmployees": 4, "companyOfficers": [{"maxAge": 1, "name": "Mr. Cary John Claiborne MBA", "age": 62, "title": "CEO, President & Director", "yearBorn": 1961, "fiscalYear": 2023, "totalPay": 728307, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Joseph A. M. Truluck M.B.A., MBA", "age": 45, "title": "CFO, Treasurer & Secretary", "yearBorn": 1978, "fiscalYear": 2023, "totalPay": 358486, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. John R. Martin J.D.", "title": "Chief Legal Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Andrew  Taubman", "title": "Vice President of Corporate Development", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Catherine  Fratila", "title": "Controller", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 4, "previousClose": 1.14, "open": 1.09, "dayLow": 1.09, "dayHigh": 1.15, "regularMarketPreviousClose": 1.14, "regularMarketOpen": 1.09, "regularMarketDayLow": 1.09, "regularMarketDayHigh": 1.15, "beta": 1.308, "forwardPE": -0.6608187, "volume": 46832, "regularMarketVolume": 46832, "averageVolume": 284572, "averageVolume10days": 50160, "averageDailyVolume10Day": 50160, "bid": 1.1, "ask": 1.15, "bidSize": 100, "askSize": 100, "marketCap": 4783640, "fiftyTwoWeekLow": 0.77, "fiftyTwoWeekHigh": 9.0, "fiftyDayAverage": 1.3168, "twoHundredDayAverage": 1.7294, "currency": "USD", "enterpriseValue": -241471, "floatShares": 4120406, "sharesOutstanding": 4233310, "sharesShort": 163332, "sharesShortPriorMonth": 163390, "sharesShortPreviousMonthDate": 1717113600, "dateShortInterest": 1719532800, "sharesPercentSharesOut": 0.038599998, "heldPercentInsiders": 0.026659999, "heldPercentInstitutions": 0.041589998, "shortRatio": 0.73, "shortPercentOfFloat": 0.0398, "impliedSharesOutstanding": 4233310, "bookValue": 1.51, "priceToBook": 0.74834436, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1711843200, "netIncomeToCommon": -11238567, "trailingEps": -4.98, "forwardEps": -1.71, "lastSplitFactor": "1:25", "lastSplitDate": 1691366400, "enterpriseToEbitda": 0.037, "52WeekChange": -0.8441379, "SandP52WeekChange": 0.24156773, "exchange": "NCM", "quoteType": "EQUITY", "symbol": "ADIL", "underlyingSymbol": "ADIL", "shortName": "Adial Pharmaceuticals, Inc", "longName": "Adial Pharmaceuticals, Inc.", "firstTradeDateEpochUtc": 1532698200, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "a144d6a7-1775-3bb1-b1ca-599a0edca1eb", "messageBoardId": "finmb_112638788", "gmtOffSetMilliseconds": -14400000, "currentPrice": 1.13, "recommendationMean": 2.5, "recommendationKey": "buy", "totalCash": 5025110, "totalCashPerShare": 1.187, "ebitda": -6463630, "quickRatio": 8.93, "currentRatio": 9.483, "returnOnAssets": -0.76329005, "returnOnEquity": -2.97258, "freeCashflow": -3287655, "operatingCashflow": -6134232, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-07-14"}]